Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

Benzinga Newsdesk www.benzinga.com Positive 83.6%

Neg 0% Neu 0% Pos 83.6%

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.